# A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus

> **NCT00203151** · PHASE2 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 340 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** edratide

## Key facts

- **NCT ID:** NCT00203151
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 340 (ACTUAL)
- **Why stopped:** TV-4710/201 did not meet its primary endpoints in patients with SLE
- **Last updated:** 2011-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203151, "A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00203151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*